Merck ’s recent announcement about dramatically cutting R&D is just the latest such move in the pharmaceutical industry. Merck joins a number of companies including Pfizer , Lilly, AstraZeneca , etc., who have reasoned that decreasing sales due to patent expirations necessitates “right sizing” its internal R&D operations. All of these companies have sought to lower costs through greater efficiencies and slimming down R&D programs. However, to meet the budget goals, far more drastic cuts are needed and so companies are eliminating a good deal of their “bricks & mortar” – the R&D labs. The labs where iconic drugs such as Singulair, Lipitor, Viagra and Celebrex no longer exist as they have fallen to the budget axe.
Hey, check out all the research scientist jobs. Post your resume today!
